Fubon Financial Holding Co (富邦金控) yesterday said that its insurance unit would weather rising COVID-19 insurance claims and no fundraising is needed.
Fubon Insurance Co (富邦產險) said it has sold about 2.31 million COVID-19 insurance policies and as of the middle of this month had paid NT$1.1 billion (US$37.09 million) of claims from 29,000 policyholders.
It pays a total of NT$50 million per day in claims, it said.
Photo: CNA
It is difficult to calculate how much more compensation it would have to pay, as local COVID-19 infections are still on the rise, with a peak not expected until next month, Fubon Insurance said.
Fubon Insurance reiterated that it would not avoid its responsibility to policyholders.
“Fubon Insurance has net value of NT$30 billion to NT$40 billion, and assets of NT$130 billion, not to mention the high net value of Fubon Financial,” Fubon Financial president Jerry Harn (韓蔚廷) told an investors’ conference amid speculation that the company would be unable to bear the burden.
Policyholders would receive compensation, Harn said.
The loss rate on COVID-19 insurance policies was about 15 percent, the company said.
Three factors would affect the figure, including the ultimate number of local infections, the government’s virus policy and clarification of disputes, it said.
If the financial pressure becomes too heavy, Fubon Insurance would consider applying to the Financial Supervisory Commission (FSC) to use part of its special reserve to write off losses, it said.
The insurer can allocate as much as NT$15.5 billion, it said.
Fubon Financial Holding reported an annual decline of 9.4 percent in net profit to NT$46.5 billion for the first quarter, mainly because of a drop of 7 percent in net profit at Fubon Life Insurance Co (富邦人壽) to NT$36.4 billion amid decreasing first-year premiums and lower returns on investments, corporate data showed.
Realized capital gains from fixed-income investments plunged about 75 percent year-on-year to NT$6.7 billion in the first quarter, the data showed.
In related news, China Life Insurance Co (中國人壽) yesterday announced that even though its insurance terms do not stipulate that it must compensate policyholders who catch COVID-19, but are not hospitalized due to the virus, it would pay those who stay home as much as it pays for hospitalizations, as long as they are prescribed drugs.
The drugs are not limited to oral antivirus drugs such as Paxlovid and molnupiravir, or a traditional Chinese compound called Taiwan Chingguan Yihau (清冠一號), or NRICM101, but policyholders should provide prescriptions, a doctor’s diagnosis and a digital COVID-19 certificate with their claims, China Life said.
The FSC has said that insurance firms can decide themselves — while adhering to the terms of their policies — whether to compensate people who catch COVID-19, but are not hospitalized.
HANDOVER POLICY: Approving the probe means that the new US administration of Donald Trump is likely to have the option to impose trade restrictions on China US President Joe Biden’s administration is set to initiate a trade investigation into Chinese semiconductors in the coming days as part of a push to reduce reliance on a technology that US officials believe poses national security risks. The probe could result in tariffs or other measures to restrict imports on older-model semiconductors and the products containing them, including medical devices, vehicles, smartphones and weaponry, people familiar with the matter said. The investigation examining so-called foundational chips could take months to conclude, meaning that any reaction to the findings would be left to the discretion of US president-elect Donald Trump’s incoming team. Biden
INVESTMENT: Jun Seki, chief strategy officer for Hon Hai’s EV arm, and his team are currently in talks in France with Renault, Nissan’s 36 percent shareholder Hon Hai Precision Industry Co (鴻海精密), the iPhone maker known as Foxconn Technology Group (富士康科技集團) internationally, is in talks with Nissan Motor Co’s biggest shareholder Renault SA about its willingness to sell its shares in the Japanese automaker, the Central News Agency (CNA) said, citing people it did not identify. Nissan and fellow Japanese automaker, Honda Motor Co, are exploring a merger that would create a rival to Toyota Motor Corp in Japan and better position the combined company to face competitive challenges around the world, people familiar with the matter said on Wednesday. However, one potential spanner in the works is
HON HAI LURKS: The ‘Nikkei’ reported that Foxconn’s interest in Nissan accelerated the Honda-merger effort out of fears it might be taken over by the Taiwanese firm Nissan Motor Co has become the latest buyout target in Japan as it explores a merger with Honda Motor Co and faces an overture from Hon Hai Precision Industry Co (鴻海精密), known as Foxconn Technology Group (富士康科技集團) internationally. Shares in Nissan yesterday jumped 24 percent, the most on record, to hit the daily limit, after the two Japanese automakers acknowledged that talks are ongoing to better position themselves for competitive challenges during a time of upheaval in the global auto industry. Foxconn — a Taipei-based manufacturer of iPhones, which has been investing heavily in factories to build electric vehicles — has also
CHIP SUBSIDY: The US funding would help alleviate the financial pressure from building two fabs in the US and should lift gross margins in 2026, the company said GlobalWafers Co (環球晶圓), the world’s third-largest silicon wafer supplier, yesterday said it is to receive US$406 million in subsidies from the US Department of Commerce for two new US fabs under the CHIPS and Science Act, with the first batch of the funds likely coming next year. The grant represents 10 percent of the planned investments of US$4 billion in advanced semiconductor wafer manufacturing facilities in Texas and Missouri, GlobalWafers said. The commerce department is to disburse the funds based on the completion of project milestones over a multiyear timeframe, the company said. Along with the tax credit, which is equal to
RSS